Literature DB >> 18537548

S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast.

Kazumori Arai1, Sachiko Takano, Takumi Teratani, Yasuhiro Ito, Toshihiro Yamada, Ryushi Nozawa.   

Abstract

S100 protein A8 and A9 naturally form a stable heterocomplex. Recently, we have proved that S100A9 overexpression in various adenocarcinomas is associated with poor tumor differentiation. In this study, we examined the relationship between the expression of each protein and the pathological parameters that reflect the aggressiveness of carcinoma, in invasive ductal carcinoma (IDC) of the breast. Serial paraffin-embedded tissue sections from 101 IDC cases were immunostained with respective monoclonal antibodies, and the results were as follows: 1) A positive correlation of immunoreactivity between S100A8 and S100A9 was noticed (r=0.873 and P<0.0001); 2) The percentage of S100A9-positive tumor cells was higher than that of S100A8-positive tumor cells (P<0.001), and S100A8 alone was not detected in any case; 3) Overlap between S100A8 and S100A9 staining patterns was found in the corresponding tissue areas, but S100A9 positivity was also observed in S100A8-negative tumor cells; 4) The immunopositivity for each protein also correlated with the mitotic activity, MIB-1 index, HER2 overexpression, node metastasis, and poor pT categories and pStage (P<0.05); 5) Co-expression of both proteins was associated with poor tumor differentiation, vessel invasion, node metastasis, and poor pStage (P<0.05). Furthermore, co-expression of the proteins was also observed in MCF-7 cells, and it was suggested that the immunolocalization is related with cell cycle. Our conclusions are as follows: 1) It is suggested that S100A8 is S100A9-dependently expressed and acquires the protein stability by S100A8/A9 heterocomplex formation; 2) S100A8 and S100A9 overexpression should be considered marker of poor prognosis in IDC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537548     DOI: 10.2174/156800908784533445

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  61 in total

1.  Analysis of differential gene expression by fiber-optic BeadArray and pathway in prolactinomas.

Authors:  Zhiquan Jiang; Songbo Gui; Yazhuo Zhang
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

2.  microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis.

Authors:  Aaron E Hoffman; Tongzhang Zheng; Chunhui Yi; Derek Leaderer; Joanne Weidhaas; Frank Slack; Yawei Zhang; Trupti Paranjape; Yong Zhu
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

3.  Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.

Authors:  Pratima Sinha; Chinonyerem Okoro; Dirk Foell; Hudson H Freeze; Suzanne Ostrand-Rosenberg; Geetha Srikrishna
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

4.  Comparison of gene expression in hepatocellular carcinoma, liver development, and liver regeneration.

Authors:  Tingting Li; Bingbing Wan; Jian Huang; Xuegong Zhang
Journal:  Mol Genet Genomics       Date:  2010-04-01       Impact factor: 3.291

5.  MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.

Authors:  I Made Winarsa Ruma; Endy Widya Putranto; Eisaku Kondo; Hitoshi Murata; Masami Watanabe; Peng Huang; Rie Kinoshita; Junichiro Futami; Yusuke Inoue; Akira Yamauchi; I Wayan Sumardika; Chen Youyi; Ken-Ichi Yamamoto; Yasutomo Nasu; Masahiro Nishibori; Toshihiko Hibino; Masakiyo Sakaguchi
Journal:  Clin Exp Metastasis       Date:  2016-05-05       Impact factor: 5.150

6.  Protein S100-A8: A potential metastasis-associated protein for breast cancer determined via iTRAQ quantitative proteomic and clinicopathological analysis.

Authors:  Jing-Min Zhong; Jing Li; An-Ding Kang; San-Qian Huang; Wen-Bin Liu; Yun Zhang; Zhi-Hong Liu; Liang Zeng
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

7.  A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants.

Authors:  Luigi De Petris; Maria Pernemalm; Göran Elmberger; Per Bergman; Lotta Orre; Rolf Lewensohn; Janne Lehtiö
Journal:  Proteome Sci       Date:  2010-02-26       Impact factor: 2.480

8.  mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer.

Authors:  Yun-Sok Ha; Min-Ju Kim; Hyung-Yoon Yoon; Ho-Won Kang; Yong-June Kim; Seok-Joong Yun; Sang-Cheol Lee; Wun-Jae Kim
Journal:  Korean J Urol       Date:  2010-01-21

9.  Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer.

Authors:  Arzu Umar; Hyuk Kang; Annemieke M Timmermans; Maxime P Look; Marion E Meijer-van Gelder; Michael A den Bakker; Navdeep Jaitly; John W M Martens; Theo M Luider; John A Foekens; Ljiljana Pasa-Tolić
Journal:  Mol Cell Proteomics       Date:  2009-03-27       Impact factor: 5.911

10.  Involvement of potential pathways in malignant transformation from oral leukoplakia to oral squamous cell carcinoma revealed by proteomic analysis.

Authors:  Zhi Wang; Xiaodong Feng; Xinyu Liu; Lu Jiang; Xin Zeng; Ning Ji; Jing Li; Longjiang Li; Qianming Chen
Journal:  BMC Genomics       Date:  2009-08-19       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.